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Abstract
Background—Clinical laboratories in Botswana have relied entirely on the reference intervals
for normal immunohaematological values provided by manufacturers' kits and textbooks.
Objectives—The aim of this study was to determine the means, medians, 2.5th and 97.5th
percentile reference intervals, for normal immunohaematological values in healthy adults in
Botswana.
Method—A total of 261 healthy participants comprising 126 men (48%) and 135 (52%) women
were enrolled in the southern part of Botswana, and immunological and haematological laboratory
parameters were measured.
Results—The mean age was 28.8 (95% Confidence Interval [CI] 27.7–29.8) years, with a
median of 27 years and a range 18–66 years. The mean haemoglobin level was significantly lower
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for women (12.4 g/dL; 95% CI 12.1% – 12.7%) than men (15.1 g/dL; 95% CI 14.9% – 15.3%).
The women's haemoglobin reference values (9.0 g/dL – 15.0 g/dL) levels were lower than
observed in predominantly White populations (12.0 g/dL – 16.0 g/dL), but comparable with
regional consensus reference intervals (9.5 g/dL – 15.8 g/dL) recently defined for East and
Southern Africa.
Conclusion—The established values provide an important tool for patient management and
could influence decisions on inclusion of participants and adverse events in clinical trials
conducted locally.
Introduction
The human immunodeficiency virus (HIV) constitutes a major public health problem in
Botswana with a prevalence of 17.6%1 in the general population and 31.8% amongst
pregnant woman.2,3 Botswana is one of the countries in Africa that has led a very high
response to the epidemic through a range of multilevel interventions, including the
widespread access to antiretrovirals (ARVs),4,5 and has built capacity to conduct
international prevention, treatment and vaccine trials.6 A valid scientific safety evaluation of
ARVs and HIV vaccines relies on the availability of locally defined reference values for
parameters of clinical interest.7
Reference intervals are essential for monitoring patho-physiological changes after infection
or disease states, or following the administration of drugs in therapeutic or clinical
interventions and vaccine studies. Several multicenter trials, including Phase I and/or Phase
II vaccine studies and global use of ARVs, have increased the need for regional and locally
established reference values.8 Reference values vary considerably in different populations,
geographical regions, climate, race and dietary habits.9,10,11,12,13,14,15 Reference intervals
studies conducted in African countries have shown differences within populations and
sometimes within sub-groups, and marked differences with values from White
populations.8,13,16,17,18 These studies have also observed significant differences with values
from developed countries, in haematologic parameters such as haemoglobin and absolute
neutrophil, which are normally used for toxicity grading in clinical trials, and consequently
have implications in patient management and the conduct of clinical trials.18,19,20,21 A
significant number of potential African volunteers are excluded from participating in
vaccine trials because screening, enrollment and follow-up monitoring is mostly based on
values derived from predominantly White populations. A study in Uganda19 documented an
exclusion rate of as high as 69% of vaccine clinical trial participants because of
haematologic abnormalities, 83% of whom could have been included in the studies if local
reference ranges were used. Kibiya et al.8 observed that the lower limit of neutrophil counts
and haemoglobin reference ranges qualify to be graded as moderate and severe adverse
events, respectively, according to the Division of AIDS (DAIDS) toxicity grading table.22
Determination of the CD4+ T-lymphocyte counts play a pivotal role on the initiation and
monitoring of patients on highly active antiretroviral therapy (HAART); hence the urgent
need for establishing CD4+ lymphocytes reference intervals for local populations. Some
studies have observed that Black people and Afro–Caribbean people have lower total white
cell counts, and neutrophil and platelet counts, than White people.9,23,24
Immunohaematological reference values for a healthy Botswanan population have never
been established formally, whereas in many African countries, it is common practice to use
reference values established in predominantly White populations, which may not be
representative of the Botswanan population (which comprises mostly Black people). In
order to conduct investigation drug (IND) and vaccine trials successfully, an assessment of
the local reference intervals is required.25,26,27 The aim of this study was to establish the
immunohaematological reference values in healthy adults in Botswana following the
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Clinical Laboratory Standards Institute (CLSI) (formerly NCCLS) guidelines28 in order to
improve patient care, the participation of individuals in clinical trials and the evaluation of
adverse events.
Materials and methods
Study design, setting and population
A cross sectional study was conducted amongst healthy adult volunteers that were recruited
at the voluntary counselling and testing center (VCT) known as Tebelopele (a Setswana
name that means ‘foresight’) from around Gaborone, the capital city of Botswana. Potential
volunteers who tested HIV-negative in a parallel testing algorithm that used Determine
HIV-1/2 (Abbott Laboratories, IL, USA) and UniGold HIV (Trinity Biotech, Ireland) rapid
test kits, were recruited into the study. The rapid HIV results were confirmed in the
laboratory by using two enzyme-linked immunosorbent assays as per national guidelines.
Study procedures
Potential apparently healthy HIV-negative volunteers who consented to participate in the
study were included. A brief screening questionnaire was administered by experienced study
nurses. The questionnaire was designed using the Clinical Laboratory Standards Institute
(CLSI) guidelines28 (formerly NCCLS) and the following categories were excluded:
• pregnant
• breastfeeding
• patients who had been inpatients in a hospital or who had been subjectively ill
during the last month
• patients receiving medical treatment
• patients who had a recent or recurrent infection, including HIV and malaria
• patients who had smoked in the hour before blood was drawn
• patients who had donated blood in the preceding month.
Participants had access to their HIV-testing results through voluntary counselling and testing
protocol, and obtained all other results through a registered physician for review and referral
to appropriate care. Participants with underlying clinical conditions were excluded from the
analysis as well.
Laboratory procedures
Blood collection and HIV serology
Approximately 15 mL whole blood was collected from the cubital vein with a vacutainer
system in K3EDTA. Samples were analysed on the day of collection. HIV status was further
confirmed in plasma from the samples by using an enzyme-linked immunosorbent assays
Vironostika HIV Uniform II plus O (BioMérieux France, Marcy l'Etoile, France) and Murex
HIV-1.2.O Murex (Biotech, Dartford, UK) according to manufacturer's instructions. A
parallel algorithm was applied and the tests were performed at the Botswana Harvard HIV
Reference Laboratory, following national guidelines that included confirmation with
Western Blot or DNA PCR for all discordant results.
Flow cytometric analysis
T-lymphocyte subsets were analysed on a FACSCalibur flow cytometer (Becton Dickinson
Immunocytometry Systems, San Jose, California) by using a four-colour
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immunofluorescence reagent (BD MultiTEST CD3 fluorescein isothiocyanate [FITC]/CD8,
phycoerythrin [PE]/CD45, peridinin chlorophyll protein [PerCP]/CD4, allophycocyanin
[APC]), and TruCOUNT tubes according to the manufacturer's instructions. The list-mode
data was acquired and analysed with MultiSET software (Becton Dickinson
Immunocytometry Systems). The instrument used was validated prior to use and it was
monitored daily with TRUcount controls materials; it was also enrolled in an external
quality assurance scheme by the United Kingdom External Quality Assessment Scheme
(UKNEQAS). Analysis was conducted by trained and competent personnel.
Haematological analysis
Haematology parameters were determined from whole blood by using the Sysmex XE-2100
(Sysmex, Kobe, Japan), according to the manufacturer's instructions. The XE-2100 is
capable of measuring 32 parameters, including the white blood cell (WBC) 5-part
differential into lymphocytes, monocytes, eosinophils, neutrophils and basophils. It also
provides a 14-parameter haemogram, as well as an integral reticulocyte analysis that
includes an immature reticulocyte fraction, a nucleated red blood cell (NRBC) count and
calculated parameters. These calculated parameters are, the mean corpuscular volume
(MCV) (fL), the corpuscular haemoglobin (MCH) (pg), the mean corpuscular haemoglobin
concentration (MCHC) (g/dL), and the RBC distribution width by standard deviation
(RDW-SD) (fL). The accuracy and precision of the instrument was monitored daily by using
commercial quality control materials, as well as quarterly through enrollment in an external
quality assurance scheme by the College of American Pathologists (CAP). Trained and
competent personnel performed the analysis.
Ethical considerations
The study was approved by the Health Research and Development Committee (HRDC) of
the Ministry of Health in Botswana. Written informed consent was obtained from
participants prior to their enrollment. Those people found to be HIV-positive were excluded
from the study, and referred for HIV care and treatment clinics for further management.
CD4 and haematology results that were obtained, were offered free of charge as per the
Botswanan guidelines.
Statistical analysis
Reference intervals were calculated according to the CLSI guidelines document C28-A2 28
by applying non-parametric methods. The medians were calculated and reference values
were determined as the 2.5th and 97.5th percentiles, respectively, of the distribution of
reference values. The mean, median, and standard deviation values were calculated for each
immunohaematological parameter. We used confidence ratio, which is the ratio of (average
confidence interval width) to (reference interval), as described by Rhoads,29 to evaluate the
impact of the sample size. CLSI recommends a minimum of 120 healthy patients per group.
The non-parametric Mann-Whitney U test was used to determine any statistically
differences between laboratory values for men and women. P-values < 0.05 were considered
significant. All statistical analyses were carried out with EP Evaluator Release 8 (David G.
Rhoads and Associates, Kennett Square, Pennsylvania, USA) and Stata 11.0 (SataCorp,
College Park, Texas, USA).
Results
Screening and enrollment started in May 2008 and ended in June 2008. A total of 294
individuals were screened: 145 men (49%) and 149 women (51%). A total of 33 (11.2%) of
screened volunteers were excluded, following enrollment based on defined exclusion
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criteria. The remaining 261 participants' samples were included in the study, and comprised
135 women (51%) and 126 men (49%). The mean age was 28.8 (95% CI, 27.7–29.8) years,
with a median of 27 and a range 18–66 years.
In our results (Table 1 and Table 2) we show the means, medians and 95th percentile
reference values, according to gender, for CD4+ and CD8+ T-lymphocytes absolute values
and percentages. The median CD4 cell count in the women (924 cells/mm3) was significant
higher than in the men (744 cells/mm3), with p < 0.05. The calculated combined reference
intervals for CD4+ and CD8+ T-lymphocytes were 261 cells/mm3 – 1667 cells/mm3and 261
cells/mm3 – 1538 cells/mm3 for men, and 268 cells/mm3 – 1667 cells/mm3 for women
(Table 1). The reference intervals for CD8+ T-lymphocytes (Table 2) were comparable to
those obtained from a blood donor population. The study furthermore shows that the CD4%
and CD8% reference intervals for women were 27–63, for men 27–60, and for both sexes
27–63 (Table 3). The CD8% reference intervals were 12–46 for women, 11–45 for men, and
11–46 for both sexes. The absolute CD4 and CD8 values for Botswana were lower than for
most African countries (Table 4).
Our research shows the reference intervals for the haematological parameters (mean; mean
s.d; and 95% CI for mean, median, range 2.5th to 97.5th percentile) partitioned by gender
(Table 5 and Table 6). The red blood cell (RBC) parameters (median haemoglobin,
haematocrit, and RBC) and WBC were statistically different according to gender (p < 0.05).
There were; however, no gender-specific differences observed for some white blood cell
(WBC) subsets (neutrophils, eosinophils, lymphocytes, reticulocytes and basophils), except
for monocytes (p = 0.0089). Our research also shows haematological reference intervals
from this study and those from certain African countries14,16,18,19 and non-African
populations (Table 7).30 The haemoglobin reference intervals were generally higher than in
East Africa, but lower than those from Ethiopia and US-based comparison populations.
Discussion
The reference intervals for immunohaematological and clinical chemistry parameters, which
may serve as Botswanan standards for the interpretation of laboratory results, were
established from 260 HIV-negative participants (134 women [52%] and 126 men [48%])
aged 18–66 years, from around Gaborone. As expected, the percentage CD4+ and CD8+ T-
lymphocytes varied less between women and men. Malone et al.31 reported large
fluctuations in repeated CD4+ cell counts in HIV-positive patients and can be explained, in
part, by CD4+ cell count diurnal cycle, and also by high variability in total lymphocyte
counts. HIV-negative women have a higher average CD4+ T-lymphocytes count than men,
which confirms the findings of Bussmann et al.32 The CD4 cell counts are lower in
Botswana than those observed in East Africa and USA. This has obvious implications on the
clinical staging of AIDS and the assessment for disease progression.
The significant gender difference in red blood cell count, haemoglobin and haematocrit,
agrees with other studies16 and with the well-established fact that men have higher values
for the red blood cell parameters than women, partly because of the influence of the
hormone androgen on erythropoiesis, and partly because of menstrual loss. The red blood
cell parameters for the Botswanan population were within the intervals for the Ethiopian
population, even though the expectation was that altitude induces erythropoiesis, which has
accounted for the red blood cell parameters of Ethiopia that were consistently higher than
those of many other African countries.16
The median haemoglobin level was significantly lower for women than for men, which is
consistent with previous fndings.8,9,21,27 The female haemoglobin reference value (9.0 g/dL
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to 15.0 g/dL) levels were lower than observed in predominantly White populations (12.0 g/
dL to 16.0 g/dL), but comparable with East African and Southern African regional
consensus reference intervals (9.5 g/dL to 15.8 g/dL) recently defined for East and Southern
Africa. The Division of AIDS (DAIDS) has haematological criteria for grading the severity
of potential vaccine-related adverse events.22 White blood cell and platelet counts, and
haemoglobin levels are used as inclusion and/or exclusion criteria in many clinical trials.
The lower limit of Botswana's normal female reference range for haemoglobin qualifies as a
moderate adverse event and a significant proportion of the woman may not qualify to be
enrolled for Phase I and/or Phase II vaccine trials.
The methodologies in this study are commonly used, and should serve well as guidelines for
the represented population. Laboratories that wish to adopt these reference intervals should
explore any differences in methodology, and should verify the transference and
appropriateness of the reference intervals to their laboratory.
Limitations of the study
Although this study meets the minimum CLSI requirements for establishing valid reference
intervals, it is be important to explore further geographic and ethic differences that may exist
within the Botswanan population. One limitation of our study is that, despite our efforts to
include only healthy subjects, the use of a questionnaire, as well as HIV screening and a
review by a physician, it was not feasible to screen for all medical conditions that might
have influenced the laboratory results. For instance, participants were not examined for
other infections such as respiratory infections, recent transient gastroenteritis and sexually
transmitted infections. All participants were adults drawn from voluntary counselling and
testing facilities. When reporting reference values, the actual representativeness of the data
is an important concern for the underlying population. As in most studies, we cannot totally
exclude the possibility that there is some sampling bias because of use of a self-selecting
population. Our analysis excluded participants who showed any signs or symptoms of
disease, however, and it is thus likely that our data are representative of healthy adults from
the southern region of Botswana. Gaborone is the capital city of Botswana and has a
diversity of ethnic groups; consequently, reference values from this region are not likely to
make a significant clinical difference. Because of access to a reference laboratory working
under ISO and GCLP standards, it was not easy to include regions that are further away
from the capital city, but this data is still considered to be a very important baseline for
similar future studies. The data are also immediately applicable in studies and clinical care
that is an improvement over the current practice of using reference values derived from
elsewhere.
Conclusion
This is the first study in Botswana to document haematological reference intervals for
healthy adults. Our study shows that clinical reference values developed within the region
are more appropriate for the Botswanan population than those adopted from developed
countries. The established values provide an important tool for patient management and
could influence decisions on the inclusion of participants, as well as the management of
adverse events. It could also improve scientific validity in clinical trials that are conducted
locally and regionally.
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